Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Non Operating Income (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non Operating Income for 13 consecutive years, with -$206000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Non Operating Income fell 174.1% to -$206000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $289000.0, a 78.59% decrease, with the full-year FY2024 number at $289000.0, down 78.59% from a year prior.
  • Non Operating Income was -$206000.0 for Q4 2024 at Traws Pharma, down from $61000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $362000.0 in Q1 2023 to a low of -$206000.0 in Q4 2024.
  • A 5-year average of $124315.8 and a median of $96000.0 in 2020 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 412.5% in 2020, then surged 31500.0% in 2022.
  • Traws Pharma's Non Operating Income stood at -$25000.0 in 2020, then skyrocketed by 96.0% to -$1000.0 in 2021, then soared by 31500.0% to $314000.0 in 2022, then dropped by 11.46% to $278000.0 in 2023, then plummeted by 174.1% to -$206000.0 in 2024.
  • Per Business Quant, the three most recent readings for TRAW's Non Operating Income are -$206000.0 (Q4 2024), $61000.0 (Q3 2024), and $205000.0 (Q2 2024).